Replies to post #2197 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Is there a difference between CD137 and CDw137?<

The Bristol-Myers drug called BMS-663513 is a CD137 antagonist, while the drug GTC is working on with the Mayo Clinic is a CD137 agonist. Same molecular target, but the two programs are otherwise unrelated.

[DewDiligence]

Correction: CapraVacca et al re CD137:

After rereading the information you furnished from clinicaltrials.gov on the Bristol-Myers BMS-663513 drug in phase-1, I see that I misspoke in message #2199 when I called this drug a CD137 antagonist. In fact, it is a CD137 agonist. I was confused by the terminology that refers to the drug as an “anti-CD137” monoclonal antibody; however, in this context, the “anti” prefix simply means that the drug is directed at the CD137 target. Apologies for the confusion.

How Bristol’s drug differs from what GTC is doing with the Mayo Clinic is something that I’ll have to investigate. Regards, Dew